Culine S, Azab M, Pietri F, Ghosn M, Ben Amor B, Lupera H, Theodore C, Renaux J, Droz J P
Département de médecine, Institut Gustave-Roussy, Villejuif, France.
Bull Cancer. 1989;76(6):583-9.
In order to compare the safety and the antiemetic effectiveness of tetracosactide (TCS) or beta 1,24 ACTH with those of dexamethasone (DXM) as an adjunct to high-dose metoclopramide, diphenhydramine and clorazepate, 33 patients receiving cisplatin based cancer chemotherapy were enrolled in a double-blind cross-over clinical trial. TCS and DXM were given intravenously, respectively at a dose of 2 mg and 20 mg, and concurrently to the cisplatin infusion. No statistically significant difference was noted between the two drugs with regard to efficacy or side effects. We conclude that TCS can serve as a substitute for DXM in combination antiemetic regimens for management of cisplatin-induced nausea and vomiting.
为比较二十四肽促皮质素（TCS）或β1,24促肾上腺皮质激素（ACTH）与地塞米松（DXM）作为大剂量甲氧氯普胺、苯海拉明和氯氮䓬辅助用药时的安全性及止吐效果，33例接受顺铂为基础的癌症化疗患者参与了一项双盲交叉临床试验。TCS和DXM分别以2 mg和20 mg的剂量静脉注射，并在输注顺铂时同时给药。两种药物在疗效或副作用方面均未观察到统计学上的显著差异。我们得出结论，在用于管理顺铂所致恶心和呕吐的联合止吐方案中，TCS可替代DXM。
